38.61MMarket Cap
LossP/E TTM
Key Figures
1.520Open
1.600High
133.07KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.76%Turnover Ratio
1.550Prev. Close
1.510Low
116.31KTurnover
LossP/E Static
3.72P/B
0.00%Div Yield TTM
-79.91%ROA
2.23052wk High
0.38Volume Ratio
-9.47MNet Profit
17.56MShares
-0.4344EPS TTM
1.66Beta
-89.97%ROE
0.85052wk Low
5.81%Amplitude
--Gross Margin
38.61MMarket Cap
3.20Reward/Risk
5.17%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
NanoViricides Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 172 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to remain stable.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NanoViricides Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
NanoViricides Inc Highlights
StrengthsRisks
NanoViricides Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NanoViricides Inc Info
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
Ticker SymbolNNVC
CompanyNanoViricides Inc
CEODiwan (Anil)
Websitehttps://www.nanoviricides.com/
Shareholders
FAQs
What is the current price of NanoViricides Inc (NNVC)?
The current price of NanoViricides Inc (NNVC) is 1.52.
What is the symbol of NanoViricides Inc?
The ticker symbol of NanoViricides Inc is NNVC.
What is the 52-week high of NanoViricides Inc?
The 52-week high of NanoViricides Inc is 2.23.
What is the 52-week low of NanoViricides Inc?
The 52-week low of NanoViricides Inc is 0.85.
What is the market capitalization of NanoViricides Inc?
The market capitalization of NanoViricides Inc is 26.72M.
Is NanoViricides Inc (NNVC) currently rated as Buy, Hold, or Sell?
According to analysts, NanoViricides Inc (NNVC) has an overall rating of Buy, with a price target of 6.00.
What is the Earnings Per Share (EPS TTM) of NanoViricides Inc (NNVC)?
The Earnings Per Share (EPS TTM) of NanoViricides Inc (NNVC) is -0.63.
